Bryostatin 1 - GPC Biotech

Drug Profile

Bryostatin 1 - GPC Biotech

Alternative Names: BMY 45618; Bryol; NSC 339555

Latest Information Update: 11 Mar 2004

Price : $50

At a glance

  • Originator Arizona State University
  • Developer GPC Biotech AG
  • Class Antineoplastics; Macrocyclic compounds
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia; Graft-versus-host disease; Malignant melanoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Renal cancer

Most Recent Events

  • 09 Mar 2004 Discontinued - Phase-II for Malignant melanoma in USA (IV)
  • 09 Mar 2004 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)
  • 09 Mar 2004 Discontinued - Phase-II for Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top